[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN)

Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,100
  • Shares Outstanding, K 80,631
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,570 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 37.33

Options Overview Details

View History
  • Implied Volatility 718.84% (+161.73%)
  • Historical Volatility 176.78%
  • IV Percentile 91%
  • IV Rank 55.65%
  • IV High 1,276.91% on 06/05/26
  • IV Low 18.59% on 02/17/26
  • Expected Move (DTE 16) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 56
  • Volume Avg (30-Day) 148
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 5,798
  • Open Int (30-Day) 4,597
  • Expected Range 2.13 to 2.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.07
  • Low Estimate $-0.09
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +25.00%
on 06/10/26
2.35 -9.38%
on 06/22/26
+0.18 (+9.54%)
since 06/01/26
3-Month
1.70 +25.00%
on 06/10/26
4.67 -54.50%
on 04/07/26
-2.24 (-51.26%)
since 04/01/26
52-Week
1.70 +25.00%
on 06/10/26
6.30 -66.27%
on 01/08/26
-0.37 (-14.66%)
since 07/01/25

Most Recent Stories

More News
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified...

NGEN : 2.09 (+1.21%)
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...

NGEN : 2.09 (+1.21%)
NervGen Announces Proposed Public Offering of Securities

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma...

NGEN : 2.09 (+1.21%)
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study...

NGEN : 2.09 (+1.21%)
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...

NGEN : 2.09 (+1.21%)
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...

NGEN : 2.09 (+1.21%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia. Primary endpoint will be the change from baseline in GRASSP...

NGEN : 2.09 (+1.21%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. ...

NGEN : 2.09 (+1.21%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading...

NGEN : 2.09 (+1.21%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 2.09 (+1.21%)
NGEN.VN : 5.150 (+3.00%)

Business Summary

Nanogen's is a supplier of molecular diagnostic tests to the medical community and to clinical researchers. They commercialize instruments, consumables, electronic microarrays and reagents through a direct sales force and distributors in North America, Europe and Asia. The Company also provide a highly...

See More

Key Turning Points

3rd Resistance Point 2.33
2nd Resistance Point 2.21
1st Resistance Point 2.14
Last Price 2.09
1st Support Level 1.95
2nd Support Level 1.83
3rd Support Level 1.76

See More

52-Week High 6.30
Fibonacci 61.8% 4.54
Fibonacci 50% 4.00
Fibonacci 38.2% 3.46
Last Price 2.09
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.